Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.
Saved in:
| Title: | Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial. |
|---|---|
| Authors: | Gomez-Mancilla B; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Dürsteler KM; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland., Vogel M; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Psychiatric Services of Thurgovia, Psychiatric Hospital Münsterlingen, Münsterlingen, Switzerland., Herdener M; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland., Torrens M; Addiction Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, University of Vic-Central de Catalunya, and Red de investigación en Atención Primaria de Adicciones (RIAPAd), Barcelona, Spain., Gálvez BP; Department of Clinical Medicine, Universidad Miguel Hernández, Edificio Muhammad Al-Shafra, Campus de San Juan, Alicante, Spain.; Addictive Behaviors Unit, Hospital Universitario San Juan, Alicante, Spain., Gual A; Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain., Corral RM; University of Buenos Aires, Buenos Aires, Argentina., Kuper EI; Centro Neurobiológico y de Stress Traumático-Biopsychomedical Research Group, Buenos Aires, Argentina., Mosca DL; Instituto Nacional Psicopatologia, Buenos Aires, Argentina., Dumitras S; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Pezous N; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Berkheimer M; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Walker E; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Gasparini F; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Cha JH; Novartis Biomedical Research, Cambridge, MA, USA., Dolmetsch R; Novartis Biomedical Research, Cambridge, MA, USA. |
| Source: | Science translational medicine [Sci Transl Med] 2025 Apr 02; Vol. 17 (792), pp. eadi4505. Date of Electronic Publication: 2025 Apr 02. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1946-6242 |
|---|---|
| DOI: | 10.1126/scitranslmed.adi4505 |
